Morgan Stanley raised the firm’s price target on Chemours to $30 from $28 and keeps an Equal Weight rating on the shares. The firm, which lowered its North American Chemicals industry view to In-Line from Attractive, sees limited base case upside in most places looking into 2024 given its expectations for largely status quo macro at least through the first half of 2024. The firm recommends remaining “barbell positioned” with grinders/compounders on one end and sentiment inflection plays on the other.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CC:
- Elastic upgraded, Alibaba downgraded: Wall Street’s top analyst calls
- Chemours upgraded to Outperform from Sector Perform at RBC Capital
- DuPont, Chemours, Corteva reach settlement agreement with state of Ohio
- Chemours, DuPont and Corteva reach settlement agreement with Ohio for $110M
- Appeals court tosses lawsuit against ‘forever chemical’ companies, Axios says